Stocks and Investing Stocks and Investing
Tue, April 5, 2022
Mon, April 4, 2022
Sun, April 3, 2022
Fri, April 1, 2022
Thu, March 31, 2022

Marc Goodman Maintained (AMLX) at Buy with Decreased Target to $31 on, Mar 31st, 2022


Published on 2024-10-27 20:15:04 - WOPRAI, Marc Goodman
  Print publication without navigation


Marc Goodman of SVB Leerink, Maintained "Amylyx Pharmaceuticals, Inc." (AMLX) at Buy with Decreased Target from $50 to $31 on, Mar 31st, 2022.

Marc has made no other calls on AMLX in the last 4 months.



There are 3 other peers that have a rating on AMLX. Out of the 3 peers that are also analyzing AMLX, 0 agree with Marc's Rating of Hold.



These are the ratings of the 3 analyists that currently disagree with Marc


  • Umer Raffat of "Evercore ISI Group" Initiated at Buy on, Wednesday, February 2nd, 2022
  • Andrew Fein of "HC Wainwright & Co." Initiated at Strong Buy and Held Target at $35 on, Tuesday, February 1st, 2022
  • Chris Shibutani of "Goldman Sachs" Initiated at Strong Buy and Held Target at $36 on, Tuesday, February 1st, 2022